Please Note: This trial is no longer enrolling new participants
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy
| Protocol No. | CTO-SNDX-6352-0504 | Scope | National |
|---|---|---|---|
| Principal Investigator | Jennifer Schwartz | Treatment Type | Treatment |
| Age Group | Adults and Children | Phase | Phase II |
